COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy